RYBREVANT®▼ (amivantamab) plus lazertinib shows longer globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor.
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate.